Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002240 · ClinicalTrials.gov registry record · Phase 2
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002240: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00002240 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002240, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.
Interventions
- DRUG Atazanavir
- DRUG Stavudine
- DRUG Didanosine
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
What the finished NCT00002240 record still lists
NCT00002240 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which Atazanavir is the first listed.
NCT00002240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002240 about?
NCT00002240 is a clinical study titled "Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs". The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor tha...
What is the current status of trial NCT00002240?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-03. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00002240?
The interventions under investigation include: Atazanavir (DRUG), Stavudine (DRUG), Didanosine (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002240?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia